Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
Location: United States, Massachusetts, Boston
Employees: 201-500
Total raised: $115M
Founded date: 2015
Investors 3
Date | Name | Website |
07.08.2021 | New Enterp... | nea.com |
- | Vida Ventu... | vidaventur... |
- | OrbiMed | orbimed.co... |
Funding Rounds 2
Date | Series | Amount | Investors |
26.02.2019 | Series B | $93M | New Enterp... |
08.11.2017 | Series A | $22M | New Enterp... |
Mentions in press and media 10
Date | Title | Description | Source |
01.03.2019 | NEA is raising its biggest fund ever – – again | New Enterprise Associates, the 41-year-old venture firm with offices in Menlo Park; San Francisco; B... | techcrunch... |
26.02.2019 | NEA Joins $93M Series B for Oyster Point | PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma, Inc., a privately held clinical-stage pharmac... | citybizlis... |
26.02.2019 | Oyster Point Raises $93M in Series B Funding | Oyster Point Pharma, Inc., a Princeton, NJ-based clinical-stage pharmaceutical company with an initi... | finsmes.co... |
26.02.2019 | Daily funding roundup - February 26th, 2019 | Elsa raised $7M; G2 Esports raised $17.3M; Tulip raised $18.4M; VAST Data raised $40M Attentive: At... | vator.tv/n... |
26.02.2019 | Oyster Point Raises $93M Series B | PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma, Inc., a privately held clinical-stage pharmac... | citybizlis... |
26.02.2019 | Term Sheet — Tuesday, February 26 | MO’ MONEY, MO’ PROBLEMS Good morning, Term Sheet readers. Paid Content Securing the enterprise wit... | fortune.co... |
09.11.2017 | Term Sheet — Thursday, November 9 | CAN TECH STARTUPS SAVE PRINT? Good morning, Term Sheet readers. Paid Content You can't secure what... | fortune.co... |
08.11.2017 | Oyster Point Pharmaceuticals Nets $22M Series A | SAN FRANCISCO, CA, Oyster Point Pharmaceuticals announced the completion of a $22 million Series A... | vcnewsdail... |
08.11.2017 | NEA Leads $22M Series A for Oyster Point Pharmaceuticals | SAN FRANCISCO--(BUSINESS WIRE)--Oyster Point Pharmaceuticals Inc., which is developing novel therapi... | citybizlis... |
07.11.2017 | Oyster Point Pharmaceuticals Completes $22M Series A Financi... | Oyster Point Pharmaceuticals Inc., a San Francisco, CA-based developer of novel therapies for dry ey... | finsmes.co... |